Lung cancer cell therapy trial halted after just 2 patients
NCT ID NCT06235242
First seen Apr 30, 2026 · Last updated May 07, 2026 · Updated 2 times
Summary
This study tested a new treatment for advanced non-small cell lung cancer using a patient's own immune cells (TILs) combined with an immunotherapy drug. The goal was to see if the combination was safe and tolerable. However, the trial was terminated early and only enrolled 2 people, so no clear conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Gobroad Hospital
Beijing, Beijing Municipality, China
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
-
Shanghai GoBroad Cancer Hospital
Shanghai, Shanghai Municipality, 200120, China
Conditions
Explore the condition pages connected to this study.